SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Stack Edward)
 

Sökning: WFRF:(Stack Edward) > Measuring PI3K Acti...

  • Martin, Neil E.Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA (författare)

Measuring PI3K Activation : Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • American Association for Cancer Research,2015
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-47170
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-47170URI
  • https://doi.org/10.1158/1541-7786.MCR-14-0569DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:Dana-Farber/Harvard Cancer Center Specialized Programs of Research Excellence (SPORE) in Prostate Cancer P50CA090381-08National Cancer Institute of the NIH UM1CA167552  R01CA141298  R01CA136578  R01CA131945  P01CA89021Prostate Cancer Foundation Young Investigator awards
  • Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and stathmin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = -0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gerke, TravisDepartment of Epidemiology, Harvard School of Public Health, Boston MA, USA (författare)
  • Sinnott, Jennifer A.Department of Epidemiology, Harvard School of Public Health, Boston MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA (författare)
  • Stack, Edward C.Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA (författare)
  • Andrén, Ove,1963-Örebro universitet,Institutionen för hälsovetenskap och medicin,Department of Urology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)oan (författare)
  • Andersson, Swen-Olof,1949-Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Department of Urology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)sfan (författare)
  • Johansson, Jan-Erik,1946-School of Health and Medical Sciences, Örebro University, Örebro, Sweden; Department of Urology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)jkjn (författare)
  • Fiorentino, MichelangeloCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Pathology Unit, Addarii Institute, S Orsola-Malpighi Hospital, Bologna, Italy (författare)
  • Finn, StephenCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Department of Pathology, Trinity College, Dublin, Ireland (författare)
  • Fedele, GiuseppeCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA (författare)
  • Stampfer, MeirDepartment of Epidemiology, Harvard School of Public Health, Boston MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA (författare)
  • Kantoff, Philip W.Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA (författare)
  • Mucci, Lorelei A.Department of Epidemiology, Harvard School of Public Health, Boston MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA (författare)
  • Loda, MassimoCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA; Broad Institute of Harvard and MIT, Cambridge MA, USA; Division of Cancer Studies, King's College London, London, United Kingdom (författare)
  • Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USADepartment of Epidemiology, Harvard School of Public Health, Boston MA, USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Molecular Cancer Research: American Association for Cancer Research13:10, s. 1431-14401541-77861557-3125

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy